Table 3.
Ongoing clinical trials about multitarget inhibition in pancreatic adenocarcinoma
| Combination | Target | Frequence of mutation1 | Setting | Clinical trial identifier2 | Expected end of accrual |
| Dovitinib | FGRFR + PDGFR + VEGFR | +, +, + | Phase II, + GEM and CAPE | NCT01497392 | Sep-16 |
| Trastuzumab + Erlotinib | EGFR2 + EGFR | +, + | Phase II, + GEM | NCT01204372 | Apr-15 |
| MEK162 + Ganitumab | MEK1 + IGF-1R | +, + | Phase II, multi-disease, chemorefractory | NCT01562899 | Apr-15 |
GEM: Gemcitabine; MEK 1: Mitogen-activated extracellular signal regulated kinase 1; CAPE: Capecitabine.
1
To obtain this parameter, a mean between the frequency of somatic mutations in the target was calculated from the paper by Biankin et al[108] and Waddel et al[109], Figure 1. Three parameter were possible: +++ ≥ 75%, ++ > 50%, + ≤ 50%;
2
Data Available from: URL: http// www.clinicaltrials.gov (last access 2015 May 24).